Hematologic Malignancy
Myelodysplastic Syndrome
CI-CAN-00001247MDN · MDSExplore in graph →
Hematologic336 active trials3 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001247MDN · MDSExplore in graph →
Clinical trials
1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (307)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00008177 | Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | completed | Phase 1 | 79 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT01519011 | Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine | completed | Phase 1 | 34 | CelgeneINDUSTRY | 1 | Nov 12, 2019 |
| clinicaltrials |
| NCT00761722 | Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma(RACE) | completed | Phase 1 | 31 | CelgeneINDUSTRY | 1 | Nov 8, 2019 | clinicaltrials |
| NCT02129101 | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | completed | Phase 1 | 63 | Mayo ClinicOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT03612739 | EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2(EPITHINK) | withdrawn | Phase 1 | 0 | Celyad Oncology SAINDUSTRY | 0 | Oct 29, 2019 | clinicaltrials |
| NCT03836690 | Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation(ToTem) | unknown | Phase 1 | 18 | University College, LondonOTHER | 1 | Oct 25, 2019 | clinicaltrials |
| NCT00101179 | MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | completed | Phase 1 | 63 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2019 | clinicaltrials |
| NCT00005946 | Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation | completed | Phase 1 | — | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT01747499 | Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation | terminated | Phase 1 / Phase 2 | 54 | Washington University School of MedicineOTHER | 1 | Oct 16, 2019 | clinicaltrials |
| NCT02053545 | Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion | withdrawn | Phase 1 / Phase 2 | 0 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Aug 30, 2019 | clinicaltrials |
| NCT01211457 | Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) | unknown | Phase 1 / Phase 2 | 65 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 16, 2019 | clinicaltrials |
| NCT00374933 | Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation | completed | Phase 1 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT00376480 | Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant | completed | Phase 1 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT03735446 | Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial | terminated | Phase 1 | 2 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 12, 2019 | clinicaltrials |
| NCT02920541 | Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome | completed | Phase 1 | 48 | Institut de Recherches Internationales ServierOTHER | 2 | May 24, 2019 | clinicaltrials |
| NCT00397579 | DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 11 | University of Texas Southwestern Medical CenterOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT01463046 | Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | completed | Phase 1 | 29 | University of California, San FranciscoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT02749708 | Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | terminated | Phase 1 | 13 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT01700751 | Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation | completed | Phase 1 | 17 | Washington University School of MedicineOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02123836 | Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome | unknown | Phase 1 | 20 | National University Hospital, SingaporeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02418000 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations | terminated | Phase 1 / Phase 2 | 27 | Spirita Oncology, LLCINDUSTRY | 1 | Mar 20, 2019 | clinicaltrials |
| NCT02492737 | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | completed | Phase 1 | 46 | Agios Pharmaceuticals, Inc.INDUSTRY | 2 | Mar 8, 2019 | clinicaltrials |
| NCT00520130 | Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01165996 | Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 4, 2019 | clinicaltrials |
| NCT00002746 | Interleukin-2 in Treating Patients With Myelodysplastic Syndrome | completed | Phase 1 | 24 | University of WashingtonOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT02678338 | CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies | completed | Phase 1 | 20 | Gilead SciencesINDUSTRY | 1 | Feb 21, 2019 | clinicaltrials |
| NCT01957644 | Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML | terminated | Phase 1 | 16 | Boehringer IngelheimINDUSTRY | 2 | Feb 8, 2019 | clinicaltrials |
| NCT01729845 | Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 52 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 7, 2019 | clinicaltrials |
| NCT02296242 | Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 53 | BioMed Valley Discoveries, IncINDUSTRY | 1 | Jan 29, 2019 | clinicaltrials |
| NCT00655395 | Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine | terminated | Phase 1 / Phase 2 | 25 | Viron Therapeutics IncINDUSTRY | 1 | Jan 28, 2019 | clinicaltrials |
| NCT01634217 | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | completed | Phase 1 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT02683395 | A Study of PLX51107 in Advanced Malignancies | terminated | Phase 1 | 50 | PlexxikonINDUSTRY | 1 | Dec 24, 2018 | clinicaltrials |
| NCT00075010 | Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT02676323 | Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome | terminated | Phase 1 | 19 | St. Jude Children's Research HospitalOTHER | 1 | Nov 14, 2018 | clinicaltrials |
| NCT00043810 | Study of Gelonin Purging of Autologous Stem Cells for Transplantation | terminated | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00005092 | Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 1 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 26, 2018 | clinicaltrials |
| NCT00003693 | Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | completed | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 25, 2018 | clinicaltrials |
| NCT02641002 | A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) | terminated | Phase 1 | 28 | CelgeneINDUSTRY | 1 | Oct 18, 2018 | clinicaltrials |
| NCT02717884 | Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)(TRANSATRA) | unknown | Phase 1 / Phase 2 | 60 | Michael LuebbertOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT01342289 | Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | completed | Phase 1 | 127 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT02550535 | A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients | completed | Phase 1 / Phase 2 | 3 | Cell Medica LtdINDUSTRY | 3 | Oct 2, 2018 | clinicaltrials |
| NCT00352001 | Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 37 | Mikkael Sekeres MDOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT | terminated | Phase 1 | 1 | Stanford UniversityOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT01422603 | Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) | completed | Phase 1 / Phase 2 | 9 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer | terminated | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 5, 2018 | clinicaltrials |
| NCT00356928 | Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies | terminated | Phase 1 | 14 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 20, 2018 | clinicaltrials |
| NCT02201329 | Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | completed | Phase 1 | 5 | Boehringer IngelheimINDUSTRY | 1 | Jul 30, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Nov 13, 2019source: clinicaltrials